Nobilis OR Inac

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

inaktivirana celična suspenzija serotipa A, seva B3263 / 91 Ornithobacterium rhinotracheale

Available from:

Intervet International BV

ATC code:

QI01AB07

INN (International Name):

adjuvanted inactivated vaccine against Ornithobacterium rhinotracheale serotype A

Therapeutic group:

Piščanec

Therapeutic area:

Imunologija za aves

Therapeutic indications:

Za pasivno imunizacijo o pitovnih piščancih, ki jih aktivno imunizacijo ženskih pitovnih rejci na zmanjšanje okužbe z Ornithobacterium rhinotracheale serotip A ko je ta zastopnik sodeluje. V situacijah na terenu se pasivna imuniteta prenese v obdobju nesnosti 43 tednov po zadnjem cepljenju brejih rejcev, kar ima za posledico trajanje pasivne imunosti v pitovnih piščancih najmanj 14 dni po izvalitvi.

Product summary:

Revision: 7

Authorization status:

Umaknjeno

Authorization date:

2003-01-24

Patient Information leaflet

                                Zdravilo nima veā dovoljenja za promet
15
B. NAVODILO ZA UPORABO
Zdravilo nima veā dovoljenja za promet
16
NAVODILO ZA UPORABO
Nobilis OR inac, emulzija za injiciranje za piščance
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
IMETNIKA DOVOLJENJA ZA PROIZVODNJO ZDRAVILA, ODGOVORNEGA ZA
SPROSTITEV SERIJ V EGP
Imetnik dovoljenja za promet z zdravilom in izdelovalec:
Intervet International
Wim de Körverstraat 35
5831 AN Boxmeer
Nizozemska
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Nobilis OR inac, emulzija za injiciranje za piščance
3.
NAVEDBA ZDRAVILNE(IH) UČINKOVIN(E) IN DRUGE(IH) SESTAVIN
V odmerku po 0,25 ml:
Inaktivirana suspenzija celic bakterije _Ornithobacterium
rhinotracheale_, serotip A, sev B3263/91
1 x 10
7
celic*
*pri preizkusu potentnosti pri piščancih spodbudi nastanek srednjega
titra, ki je najmanj 11,2 (log
2
)
Redko tekoči parafin:
107,21 mg
Sledi formaldehida
4.
INDIKACIJE
Pasivna imunizacija brojlerjev z aktivno imunizacijo živali ženskega
spola v brojlerskih matičnih jatah
za zmanjšanje okužbe z _Ornithobacterium rhinotracheale_ serotipa A,
kadar je ta bakterija prisotna.
V razmerah na farmi se pasivna imunost prenaša v obdobju valjenja 43
tednov po zadnjem cepljenju
brojlerskih matičnih jat, tako da traja pasivna imunost brojlerjev
najmanj 14 dni po izvalitvi.
5.
KONTRAINDIKACIJE
Ne uporabite v obdobju valjenja.
6.
NEŽELENI UČINKI
Pri laboratorijskih preskusih so pri posmrtni preiskavi zasledili
prehodno lokalno oteklino pri 40 %
živali, ki je trajala najmanj 14 dni po subkutanem cepljenju. V
razmerah na farmi so poročali o
sporadičnih lokalnih in sistemskih kliničnih reakcijah.
Če opazite kakršne koli resne stranske učinke ali druge učinke, ki
niso omenjeni v teh navodilih za
uporabo, obvestite svojega veterinarja.
Zdravilo nima veā dovoljenja za promet
17
7.
CILJNE ŽIVALSKE VRSTE
Piščanci
8.
ODMERKI ZA POSAMEZNE ŽIVALSKE VRSTE TER POT(I) IN NAČIN UPORABE
ZDRAVILA
Enkratni odmerek po 0,25 ml.
Subkutano na vratu ali intramuskularno v prs
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                Zdravilo nima veā dovoljenja za promet
1
DODATEK I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 01-10-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 01-10-2022
Public Assessment Report Public Assessment Report Bulgarian 03-10-2022
Patient Information leaflet Patient Information leaflet Spanish 01-10-2022
Public Assessment Report Public Assessment Report Spanish 03-10-2022
Patient Information leaflet Patient Information leaflet Czech 01-10-2022
Public Assessment Report Public Assessment Report Czech 03-10-2022
Patient Information leaflet Patient Information leaflet Danish 01-10-2022
Public Assessment Report Public Assessment Report Danish 03-10-2022
Patient Information leaflet Patient Information leaflet German 01-10-2022
Public Assessment Report Public Assessment Report German 03-10-2022
Patient Information leaflet Patient Information leaflet Estonian 01-10-2022
Public Assessment Report Public Assessment Report Estonian 03-10-2022
Patient Information leaflet Patient Information leaflet Greek 01-10-2022
Public Assessment Report Public Assessment Report Greek 03-10-2022
Patient Information leaflet Patient Information leaflet English 01-10-2022
Public Assessment Report Public Assessment Report English 03-10-2022
Patient Information leaflet Patient Information leaflet French 01-10-2022
Public Assessment Report Public Assessment Report French 03-10-2022
Patient Information leaflet Patient Information leaflet Italian 01-10-2022
Public Assessment Report Public Assessment Report Italian 03-10-2022
Patient Information leaflet Patient Information leaflet Latvian 01-10-2022
Public Assessment Report Public Assessment Report Latvian 03-10-2022
Patient Information leaflet Patient Information leaflet Lithuanian 01-10-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 01-10-2022
Public Assessment Report Public Assessment Report Lithuanian 03-10-2022
Patient Information leaflet Patient Information leaflet Hungarian 01-10-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 01-10-2022
Public Assessment Report Public Assessment Report Hungarian 03-10-2022
Patient Information leaflet Patient Information leaflet Maltese 01-10-2022
Public Assessment Report Public Assessment Report Maltese 03-10-2022
Patient Information leaflet Patient Information leaflet Dutch 01-10-2022
Public Assessment Report Public Assessment Report Dutch 03-10-2022
Patient Information leaflet Patient Information leaflet Polish 01-10-2022
Public Assessment Report Public Assessment Report Polish 03-10-2022
Patient Information leaflet Patient Information leaflet Portuguese 01-10-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 01-10-2022
Public Assessment Report Public Assessment Report Portuguese 03-10-2022
Patient Information leaflet Patient Information leaflet Romanian 01-10-2022
Public Assessment Report Public Assessment Report Romanian 03-10-2022
Patient Information leaflet Patient Information leaflet Slovak 01-10-2022
Public Assessment Report Public Assessment Report Slovak 03-10-2022
Patient Information leaflet Patient Information leaflet Finnish 01-10-2022
Public Assessment Report Public Assessment Report Finnish 03-10-2022
Patient Information leaflet Patient Information leaflet Swedish 01-10-2022
Public Assessment Report Public Assessment Report Swedish 03-10-2022